Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever

Hanne Van Gorp, Linyan Huang, Pedro Saavedra, Marnik Vuylsteke, Tomoko Asaoka, Giusi Prencipe, Antonella Insalaco, Benson Ogunjimi, Jerold Jeyaratnam, Ilaria Cataldo, Peggy Jacques, Karim Vermaelen, Melissa Dullaers, Rik Joos, Vito Sabato, Alessandro Stella, Joost Frenkel, Fabrizio De Benedetti, Joke Dehoorne, Filomeen Haerynck, Giuseppe Calamita, Piero Portincasa, Mohamed Lamkanfi, Hanne Van Gorp, Linyan Huang, Pedro Saavedra, Marnik Vuylsteke, Tomoko Asaoka, Giusi Prencipe, Antonella Insalaco, Benson Ogunjimi, Jerold Jeyaratnam, Ilaria Cataldo, Peggy Jacques, Karim Vermaelen, Melissa Dullaers, Rik Joos, Vito Sabato, Alessandro Stella, Joost Frenkel, Fabrizio De Benedetti, Joke Dehoorne, Filomeen Haerynck, Giuseppe Calamita, Piero Portincasa, Mohamed Lamkanfi

Abstract

Background and objective: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AID) worldwide. The disease is caused by mutations in the MEFV gene encoding the inflammasome sensor Pyrin. Clinical diagnosis of FMF is complicated by overlap in symptoms with other diseases, and interpretation of genetic testing is confounded by the lack of a clear genotype-phenotype association for most of the 340 reported MEFV variants. In this study, the authors designed a functional assay and evaluated its potential in supporting FMF diagnosis.

Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from patients with Pyrin-associated autoinflammation with an FMF phenotype (n=43) or with autoinflammatory features not compatible with FMF (n=8), 10 asymptomatic carriers and 48 healthy donors. Sera were obtained from patients with distinct AIDs (n=10), and whole blood from a subset of patients and controls. The clinical, demographic, molecular genetic factors and other characteristics of the patient population were assessed for their impact on the diagnostic test read-out. Interleukin (IL)-1β and IL-18 levels were measured by Luminex assay.

Results: The ex vivo colchicine assay may be performed on whole blood or PBMC. The functional assay robustly segregated patients with FMF from healthy controls and patients with related clinical disorders. The diagnostic test distinguished patients with classical FMF mutations (M694V, M694I, M680I, R761H) from patients with other MEFV mutations and variants (K695R, P369S, R202Q, E148Q) that are considered benign or of uncertain clinical significance.

Conclusion: The ex vivo colchicine assay may support diagnosis of FMF and functional subtyping of Pyrin-associated autoinflammation.

Keywords: familial mediterranean fever; fever syndromes; inflammation.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Diagnosis of familial Mediterranean fever (FMF) using a functional assay. (A) Peripheral blood mononuclear cells from healthy donors (n=48) and patients with FMF (n=43) were treated for 5 hours with either Clostridium difficile toxin A (TcdA) alone or with TcdA in combination with colchicine before culture supernatants were analysed for interleukin (IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each cytokine was calculated. Data are combined from multiple experiments. (B) For both parameters, the receiver operating characteristic (ROC) curve was calculated, as well as the area under curve (AUC). (C) For both parameters, the Youden index was calculated to determine the most appropriate cut-off point, given the sum of sensitivity and specificity being maximum.
Figure 2
Figure 2
Functional stratification of patients with Pyrin-associated autoinflammatory disease correlates with MEFV genetic variants. (A) Combined representation of interleukin (IL)-1β and IL-18 ratios of the ex vivo colchicine assay with peripheral blood mononuclear cells from healthy donors (n=48) and the patient group composed of patients with MEFV gene variants that presented with either a familial Mediterranean fever (FMF) phenotype (n=43) or with autoinflammatory features not compatible with FMF (n=8). Cut-off points as determined by the Youden index are indicated. (B) Analysis of variance for the patient group represented by the p value of the F test. Regression analysis for potential correlation between the assay and clinical response to colchicine tested at 5% significance level. (C) Representation of the functional assay with patient data being separated based on MEFV variants.
Figure 3
Figure 3
Functional stratification of familial Mediterranean fever (FMF) patients from healthy donors, pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA), and mevalonate kinase deficiency (MKD) patients. Peripheral blood mononuclear cells from controls, patients with FMF, and patients with PAPA (A) or patients with MKD (B) were treated for 5 hours with either Clostridium difficile toxin A (TcdA) alone or TcdA in combination with colchicine before culture supernatants were analysed for interleukin (IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each cytokine was calculated.
Figure 4
Figure 4
Functional familial Mediterranean fever (FMF) screening in human whole blood. Fresh, undiluted whole blood from controls (n=8) and patients with FMF(n=7) was treated for 24 hours either with Clostridiumdifficiletoxin A (TcdA) alone or TcdA in combination with colchicine before culture supernatants were analysed for interleukin (IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each cytokine was calculated. Results are combined from four independent experiments.

References

    1. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297. 10.1371/journal.pmed.0030297
    1. Masters SL, Simon A, Aksentijevich I, et al. . Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009;27:621–68. 10.1146/annurev.immunol.25.022106.141627
    1. Manthiram K, Zhou Q, Aksentijevich I, et al. . The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 2017;18:832–42. 10.1038/ni.3777
    1. Van Gorp H, Van Opdenbosch N, Lamkanfi M. Inflammasome-Dependent cytokines at the crossroads of health and autoinflammatory disease. Cold Spring Harb Perspect Biol 2017.
    1. Van Gijn ME, Ceccherini I, Shinar Y, et al. . New workflow for classification of genetic variants' pathogenicity applied to hereditary recurrent fevers by the International Study Group for systemic autoinflammatory diseases (INSAID). J Med Genet 2018;55:530–7. 10.1136/jmedgenet-2017-105216
    1. Shinar Y, Obici L, Aksentijevich I, et al. . Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012;71:1599–605. 10.1136/annrheumdis-2011-201271
    1. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014;10:135–47. 10.1038/nrrheum.2013.174
    1. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302. 10.1056/NEJM197212212872514
    1. Zemer D, Pras M, Sohar E, et al. . Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001–5. 10.1056/NEJM198604173141601
    1. Özçakar ZB, Özdel S, Yılmaz S, et al. . Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 2016;35:441–6. 10.1007/s10067-014-2772-2
    1. van der Hilst JC, Moutschen M, Messiaen PE, et al. . Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 2016;10:75–80. 10.2147/BTT.S102954
    1. De Benedetti F, Gattorno M, Anton J, et al. . Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 2018;378:1908–19. 10.1056/NEJMoa1706314
    1. Ben-Zvi I, Kukuy O, Giat E, et al. . Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2017;69:854–62. 10.1002/art.39995
    1. Balow JE, Shelton DA, Orsborn A, et al. . A high-resolution genetic map of the familial Mediterranean fever candidate region allows identification of haplotype-sharing among ethnic groups. Genomics 1997;44:280–91. 10.1006/geno.1997.4860
    1. French FMF Consortium A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25–31. 10.1038/ng0997-25
    1. Milhavet F, Cuisset L, Hoffman HM, et al. . The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29:803–8. 10.1002/humu.20720
    1. Tchernitchko D, Goossens M, Wajcman H. In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics. Clin Chem 2004;50:1974–8. 10.1373/clinchem.2004.036053
    1. Stella A, Cortellessa F, Scaccianoce G, et al. . Familial Mediterranean fever: breaking all the (genetic) rules. Rheumatology 2018.
    1. Schaner P, Richards N, Wadhwa A, et al. . Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet 2001;27:318–21. 10.1038/85893
    1. Park YH, Wood G, Kastner DL, et al. . Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016;17:914–21. 10.1038/ni.3457
    1. Xu H, Yang J, Gao W, et al. . Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature 2014;513:237–41. 10.1038/nature13449
    1. Masters SL, Lagou V, Jéru I, et al. . Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med 2016;8:332–45. 10.1126/scitranslmed.aaf1471
    1. Gao W, Yang J, Liu W, et al. . Site-Specific phosphorylation and microtubule dynamics control pyrin inflammasome activation. Proc Natl Acad Sci U S A 2016;113:E4857–66. 10.1073/pnas.1601700113
    1. Van Gorp H, Saavedra PHV, de Vasconcelos NM, et al. . Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation. Proc Natl Acad Sci U S A 2016;113:14384–9. 10.1073/pnas.1613156113
    1. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417–26. 10.1016/s1097-2765(02)00599-3
    1. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 2016;16:407–20. 10.1038/nri.2016.58
    1. Shi J, Zhao Y, Wang K, et al. . Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015;526:660–5. 10.1038/nature15514
    1. Kayagaki N, Stowe IB, Lee BL, et al. . Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015;526:666–71. 10.1038/nature15541
    1. Gogtay NJ. Statistical Evaluation of Diagnostic Tests - Part 2 [Pre-test and post-test probability and odds, Likelihood ratios, Receiver Operating Characteristic Curve, Youden's Index and Diagnostic test biases]. J Assoc Physicians India 2017;65:86–91.
    1. Gogtay NJ, Thatte UM. Statistical evaluation of diagnostic tests (Part 1): sensitivity, specificity, positive and negative predictive values. J Assoc Physicians India 2017;65:80–4.
    1. Allen JN, Herzyk DJ, Wewers MD. Colchicine has opposite effects on interleukin-1 beta and tumor necrosis factor-alpha production. Am J Physiol 1991;261:L315–21. 10.1152/ajplung.1991.261.4.L315
    1. Ferrua B, Manie S, Doglio A, et al. . Stimulation of human interleukin 1 production and specific mRNA expression by microtubule-disrupting drugs. Cell Immunol 1990;131:391–7. 10.1016/0008-8749(90)90263-Q
    1. Manié S, Schmid-Alliana A, Kubar J, et al. . Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-alpha. Involvement of protein kinase A stimulation. J Biol Chem 1993;268:13675–81.
    1. Ozturk C, Halicioglu O, Coker I, et al. . Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from Western Anatolia, Turkey. Clin Rheumatol 2012;31:493–501. 10.1007/s10067-011-1876-1
    1. Giaglis S, Papadopoulos V, Kambas K, et al. . Mefv alterations and population genetics analysis in a large cohort of Greek patients with familial Mediterranean fever. Clin Genet 2007;71:458–67. 10.1111/j.1399-0004.2007.00789.x
    1. Mattit H, Joma M, Al-Cheikh S, et al. . Familial Mediterranean fever in the Syrian population: gene mutation frequencies, carrier rates and phenotype-genotype correlation. Eur J Med Genet 2006;49:481–6. 10.1016/j.ejmg.2006.03.002
    1. Wise CA, Gillum JD, Seidman CE, et al. . Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961–9. 10.1093/hmg/11.8.961
    1. Shoham NG, Centola M, Mansfield E, et al. . Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A 2003;100:13501–6. 10.1073/pnas.2135380100
    1. Mandey SHL, Kuijk LM, Frenkel J, et al. . A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006;54:3690–5. 10.1002/art.22194
    1. Akula MK, Shi M, Jiang Z, et al. . Control of the innate immune response by the mevalonate pathway. Nat Immunol 2016;17:922–9. 10.1038/ni.3487
    1. van der Meer JW, Vossen JM, Radl J, et al. . Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984;1:1087–90. 10.1016/S0140-6736(84)92505-4
    1. Drenth JP, Cuisset L, Grateau G, et al. . Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International hyper-IgD Study Group. Nat Genet 1999;22:178–81. 10.1038/9696
    1. Houten SM, Kuis W, Duran M, et al. . Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999;22:175–7. 10.1038/9691
    1. Ammann S, Elling R, Gyrd-Hansen M, et al. . A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol 2014;176:394–400. 10.1111/cei.12306
    1. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001;9:473–83. 10.1038/sj.ejhg.5200658
    1. Yilmaz E, Ozen S, Balci B, et al. . Mutation frequency of familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001;9:553–5. 10.1038/sj.ejhg.5200674
    1. Ben-Chetrit E, Lerer I, Malamud E, et al. . The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat 2000;15:385–6. 10.1002/(SICI)1098-1004(200004)15:4<385::AID-HUMU22>;2-A
    1. Gangemi S, Manti S, Procopio V, et al. . Lack of clear and univocal genotype-phenotype correlation in familial Mediterranean fever patients: a systematic review. Clin Genet 2018;94:81–94. 10.1111/cge.13223
    1. Singh S, Chaudhary J, Meyerhoff J. A rare complex mutation in FMF gene; genetics and treatment decisions in familial Mediterranean fever patients. Int J Clin Rheumtol 2018;13:193–6. 10.4172/1758-4272.1000186
    1. Bonfrate L, Scaccianoce G, Palasciano G, et al. . A novel cluster of patients with familial Mediterranean fever (FMF) in southern Italy. Eur J Clin Invest 2017;47:622–9. 10.1111/eci.12783
    1. Liantinioti G, Argyris AA, Protogerou AD, et al. . The role of colchicine in the treatment of autoinflammatory diseases. Curr Pharm Des 2018;24:690–4. 10.2174/1381612824666180116095658
    1. Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341–50. 10.1016/j.semarthrit.2015.06.013

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren